Qi Diagnostics Limited Awarded as “Most Innovative Medical Diagnostics Developer 2025 – East Asia”
(19 May 2025)
Hong Kong, May 19, 2025 – Qi Diagnostics Limited, a medical technology innovator based in Hong Kong, has been awarded the prestigious title of “Most Innovative Medical Diagnostics Developer 2025 – East Asia” at the Biotechnology & Lifesciences Awards 2025. The awards, now in their 17th year, are dedicated to honouring the visionary companies and innovators at the forefront of the Scientific Industry.
This award recognizes Qi Diagnostics’ groundbreaking work in non-invasive breath-based diagnostic technologies, particularly in the early detection of cancer. The company’s development of cancer-specific breath markers and a point-of-care breathalyzer device has demonstrated over 90% accuracy in clinical validation, comparable to the accuracy of CT scans, while being far more accessible and user-friendly. The technology represents a major advancement in preventive and community-level healthcare.
This recognition reaffirms the company’s leadership in diagnostic innovation across East Asia. Qi Diagnostics will continue to advance nanosensor-based breath diagnostics and contribute to the global evolution of personalized, non-invasive medical technologies.
Biotechnology & Lifesciences Awards 2025 official press release: https://ghpnews.digital/winners/qi-diagnostics-limited/
Qi Diagnostics Limited 榮獲「2025年東亞最具創新醫療診斷開發商」殊榮
（2025年5月19日）
香港醫療科技創新企業 Qi Diagnostics Limited 榮獲《Biotechnology & Lifesciences Awards 2025》頒發「2025年東亞最具創新醫療診斷開發商」殊榮。該獎項已踏入第 17 屆，旨在表揚於科學產業領域中具遠見的企業與創新者。
此項榮譽肯定了 Qi Diagnostics Limited 於無創呼氣診斷技術方面的突破性成果，尤其是在癌症早期偵測領域的創新應用。公司研發的癌症專屬呼氣標記（cancer-specific breath markers）及即時呼氣檢測裝置，在臨床驗證中展現出超過 90% 的準確度，準確率可媲美電腦斷層掃描（CT Scan），但使用上更為簡便、普及且非侵入性，為預防醫療與基層健康管理帶來重大突破。
是次國際性認可再次確認了 Qi Diagnostics Limited 於東亞地區醫療診斷創新領域的領導地位。公司將持續推動納米感測呼氣診斷技術的發展，並致力促進全球個人化及無創醫療技術的演進與應用。
官方獲獎公告連結：https://ghpnews.digital/winners/qi-diagnostics-limited/